Paper: Are Pivotal Trials for Drugs Approved for Leukemia, Myelodysplastic Syndromes, and Multiple Myeloma Representative of the Population Demographics Affected By These Diseases?
This is a very interesting retrospective study were they looked at malignant hematology clinical trials between 2017 and 2021 which led to FDA drug approval and compared the demographics of the trial to those found in the SEER database. African Americans had an 86.5% lower percent representation in multiple myeloma and 68% lower in AML.
